Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA, United States of America.
Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia at Augusta University, Augusta, GA, United States of America.
Bone. 2024 Sep;186:117147. doi: 10.1016/j.bone.2024.117147. Epub 2024 Jun 10.
We and others have seen that osteocytes sense high-impact osteogenic mechanical loading via transient plasma membrane disruptions (PMDs) which initiate downstream mechanotransduction. However, a PMD must be repaired for the cell to survive this wounding event. Previous work suggested that the protein Prkd1 (also known as PKCμ) may be a critical component of this PMD repair process, but the specific role of Prkd1 in osteocyte mechanobiology had not yet been tested. We treated MLO-Y4 osteocytes with Prkd1 inhibitors (Go6976, kbNB 142-70, staurosporine) and generated an osteocyte-targeted (Dmp1-Cre) Prkd1 conditional knockout (CKO) mouse. PMD repair rate was measured via laser wounding and FM1-43 dye uptake, PMD formation and post-wounding survival were assessed via fluid flow shear stress (50 dyn/cm), and in vitro osteocyte mechanotransduction was assessed via measurement of calcium signaling. To test the role of osteocyte Prkd1 in vivo, Prkd1 CKO and their wildtype (WT) littermates were subjected to 2 weeks of unilateral axial tibial loading and loading-induced changes in cortical bone mineral density, geometry, and formation were measured. Prkd1 inhibition or genetic deletion slowed osteocyte PMD repair rate and impaired post-wounding cell survival. These effects could largely be rescued by treating osteocytes with the FDA-approved synthetic copolymer Poloxamer 188 (P188), which was previously shown to facilitate membrane resealing and improve efficiency in the repair rate of PMD in skeletal muscle myocytes. In vivo, while both WT and Prkd1 CKO mice demonstrated anabolic responses to tibial loading, the magnitude of loading-induced increases in tibial BMD, cortical thickness, and periosteal mineralizing surface were blunted in Prkd1 CKO as compared to WT mice. Prkd1 CKO mice also tended to show a smaller relative difference in the number of osteocyte PMD in loaded limbs and showed greater lacunar vacancy, suggestive of impaired post-wounding osteocyte survival. While P188 treatment rescued loading-induced increases in BMD in the Prkd1 CKO mice, it surprisingly further suppressed loading-induced increases in cortical bone thickness and cortical bone formation. Taken together, these data suggest that Prkd1 may play a pivotal role in the regulation and repair of the PMD response in osteocytes and support the idea that PMD repair processes can be pharmacologically targeted to modulate downstream responses, but suggest limited utility of PMD repair-promoting P188 in improving bone anabolic responses to loading.
我们和其他人已经发现,破骨细胞通过瞬时质膜破裂(PMD)感知高冲击成骨机械加载,从而启动下游机械转导。然而,细胞要在这种创伤事件中存活下来,就必须修复 PMD。先前的工作表明,蛋白激酶 D1(也称为 PKCμ)可能是 PMD 修复过程的关键组成部分,但 Prkd1 在破骨细胞机械生物学中的具体作用尚未得到测试。我们用 Prkd1 抑制剂(Go6976、kbNB142-70、staurosporine)处理 MLO-Y4 破骨细胞,并生成破骨细胞靶向(Dmp1-Cre)Prkd1 条件性敲除(CKO)小鼠。通过激光划痕测量 PMD 修复率,通过流体剪切力(50dyn/cm)评估 PMD 形成和创伤后存活,通过钙信号测量评估体外破骨细胞机械转导。为了测试破骨细胞中 Prkd1 的作用,Prkd1 CKO 及其野生型(WT)同窝仔鼠接受 2 周单侧胫骨轴向加载,测量皮质骨骨密度、几何形状和形成的加载诱导变化。Prkd1 抑制或基因缺失会降低破骨细胞 PMD 修复率并损害创伤后细胞存活。用 FDA 批准的合成共聚物泊洛沙姆 188(P188)治疗可在很大程度上挽救这些作用,先前的研究表明 P188 有助于膜重封并提高骨骼肌肌细胞 PMD 修复率的效率。在体内,虽然 WT 和 Prkd1 CKO 小鼠均对胫骨加载表现出合成代谢反应,但与 WT 小鼠相比,Prkd1 CKO 小鼠的加载诱导的胫骨骨密度、皮质厚度和骨膜矿化表面增加幅度较小。Prkd1 CKO 小鼠的破骨细胞 PMD 数量的加载诱导差异也较小,骨陷窝空位较大,提示创伤后破骨细胞存活受损。虽然 P188 治疗可挽救 Prkd1 CKO 小鼠的加载诱导的骨密度增加,但它出人意料地进一步抑制了皮质骨厚度和皮质骨形成的加载诱导增加。总之,这些数据表明,Prkd1 可能在破骨细胞中 PMD 反应的调节和修复中发挥关键作用,并支持 PMD 修复过程可以通过药理学靶向来调节下游反应的观点,但表明促进 PMD 修复的 P188 在改善对加载的骨合成反应方面的应用有限。